Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ENMD 1198

Drug Profile

ENMD 1198

Alternative Names: ENMD-1198

Latest Information Update: 18 Jun 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EntreMed
  • Developer CASI Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Cancer

Most Recent Events

  • 16 Jun 2014 EntreMed is now called CASI Pharmaceuticals
  • 19 Dec 2008 Phase-I development is ongoing in USA
  • 16 Apr 2008 Pharmacodynamics data from a preclinical trial in Cancer presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top